Fever and Rigidity in Critical Care: A Comprehensive Review

Dr Neeraj Manikath , Claude.ai

Abstract

Fever accompanied by rigidity represents a critical diagnostic challenge in intensive care settings, encompassing a spectrum from common infectious etiologies to life-threatening neurological emergencies. This review synthesizes current evidence on the pathophysiology, differential diagnosis, and management of fever-rigidity syndromes in critically ill patients, with emphasis on rapid recognition and treatment of time-sensitive conditions. We highlight diagnostic pearls, clinical pitfalls, and evidence-based management strategies essential for critical care practitioners.

Keywords: Fever, rigidity, neuroleptic malignant syndrome, serotonin syndrome, malignant hyperthermia, meningitis, tetanus, critical care

Introduction

The constellation of fever and rigidity in the intensive care unit (ICU) demands immediate attention, as it may herald conditions requiring urgent intervention to prevent permanent neurological damage or death. While fever alone is common in critical care—occurring in 26-70% of ICU patients¹—the addition of muscular rigidity significantly narrows the differential diagnosis and elevates clinical concern.

Rigidity, distinct from spasticity or dystonia, refers to increased resistance to passive movement that persists throughout the range of motion in both flexor and extensor muscle groups. When coupled with fever, this presentation suggests either central nervous system (CNS) infection, drug-induced hyperthermic syndromes, or metabolic/toxic encephalopathies.

Pearl #1: The temporal relationship between fever onset and rigidity development is diagnostically crucial. Simultaneous onset suggests infectious/inflammatory etiologies, while rigidity preceding fever points toward drug-induced hyperthermic syndromes.

Pathophysiology

Thermoregulation and Hyperthermia

True fever results from cytokine-mediated elevation of the hypothalamic set-point, primarily through prostaglandin E₂ (PGE₂) production.² Hyperthermia, conversely, represents failure of heat dissipation mechanisms despite normal hypothalamic function. This distinction has therapeutic implications: antipyretics effectively reduce true fever but are ineffective in hyperthermia.

Mechanisms of Rigidity

Rigidity in febrile states arises through several mechanisms:

Direct CNS inflammation: Meningeal irritation, encephalitis
Neurotransmitter dysregulation: Dopamine depletion (NMS), serotonin excess (serotonin syndrome)
Peripheral hypermetabolism: Malignant hyperthermia, thyroid storm
Inhibitory pathway dysfunction: Tetanus, strychnine poisoning

Hack #1: Remember "DIMS" for rigidity mechanisms: Direct inflammation, Inhibition loss, Metabolic excess, Synaptic dysfunction.

Differential Diagnosis

Life-Threatening Conditions Requiring Immediate Recognition

1. Neuroleptic Malignant Syndrome (NMS)

NMS represents an idiosyncratic reaction to dopamine receptor antagonists, occurring in 0.01-3.23% of patients exposed to antipsychotics.³ The condition can develop within hours to weeks of drug initiation or dose escalation.

Clinical Features:

Classic tetrad: Hyperthermia, rigidity, altered mental status, autonomic instability
"Lead-pipe" rigidity affecting all muscle groups
Temperatures often >38.5°C, may exceed 42°C
Diaphoresis, tachycardia, labile blood pressure
Mutism or profound encephalopathy

Diagnostic Criteria (DSM-5):

Recent dopamine antagonist exposure
Severe rigidity
Fever
Plus two or more: diaphoresis, dysphagia, tremor, incontinence, altered consciousness, elevated CK, leukocytosis

Laboratory Findings:

Creatine kinase (CK) elevation: typically >1000 U/L, often >10,000 U/L
Metabolic acidosis
Acute kidney injury (from rhabdomyolysis)
Leukocytosis (15,000-30,000/μL)

Pearl #2: NMS can occur with "atypical" antipsychotics, antiemetics (metoclopramide, prochlorperazine), and even after withdrawal of dopaminergic agents in Parkinson's disease. Always review the medication history for the preceding 4 weeks.

Management:

Immediate discontinuation of causative agent
Aggressive cooling: External and internal cooling measures
Dantrolene sodium: 1-2.5 mg/kg IV q6h (up to 10 mg/kg/day)⁴
- Mechanism: Inhibits calcium release from sarcoplasmic reticulum
- Continue until symptoms resolve, then taper
Bromocriptine: 2.5-10 mg PO/NG TID (dopamine agonist)
Amantadine: 100-200 mg PO/NG BID (alternative dopamine agonist)
Benzodiazepines: For agitation and autonomic instability
Supportive care: Aggressive fluid resuscitation, monitoring for rhabdomyolysis complications

Hack #2: NMS mortality has decreased from 20-30% to <10% with early recognition and dantrolene therapy. Don't wait for laboratory confirmation—treat empirically when clinical suspicion is high.

2. Serotonin Syndrome

Serotonin syndrome results from excessive serotonergic activity, typically following therapeutic medication use, overdose, or drug-drug interactions. The incidence has increased with widespread use of selective serotonin reuptake inhibitors (SSRIs).⁵

**Clinical Features (Hunter Criteria):**⁶ In the presence of serotonergic agent use:

Spontaneous clonus, OR
Inducible clonus PLUS agitation or diaphoresis, OR
Ocular clonus PLUS agitation or diaphoresis, OR
Tremor PLUS hyperreflexia, OR
Hypertonia PLUS temperature >38°C PLUS ocular clonus or inducible clonus

Distinguishing Features from NMS:

Onset: Hours (vs. days-weeks for NMS)
Neuromuscular findings: Hyperreflexia, clonus, mydriasis (vs. hyporeflexia in NMS)
Rigidity distribution: Lower extremity predominance (vs. generalized in NMS)
GI symptoms: Diarrhea common (rare in NMS)

Pearl #3: The triad of hyperreflexia, clonus, and clonus is nearly pathognomonic for serotonin syndrome. Check for ankle clonus—if it persists >5 beats, serotonin syndrome is likely.

Causative Agents:

SSRIs, SNRIs, tricyclic antidepressants
MAO inhibitors (especially with combinations)
Tramadol, meperidine, fentanyl
Linezolid (weak MAO inhibitor)
Dextromethorphan, ondansetron
MDMA (ecstasy), amphetamines
St. John's wort

Management:

Discontinuation of all serotonergic agents
Supportive care: Benzodiazepines for agitation, cooling measures
Cyproheptadine: 12 mg initial dose, then 2 mg q2h (max 32 mg/day)
- 5-HT₂A antagonist
- Available only in oral formulation
Avoid physical restraints: May worsen hyperthermia
Intubation/paralysis: For severe cases with extreme hyperthermia

Oyster #1: Serotonin syndrome severity ranges from mild (tremor, tachycardia) to life-threatening. Mild cases may be managed with observation alone after drug discontinuation, but severe cases require ICU admission. The key is not to miss moderate cases that can rapidly progress.

3. Malignant Hyperthermia (MH)

MH is a rare pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine, with an incidence of 1:5,000 to 1:100,000 anesthetics.⁷ Mutations in the RYR1 gene (encoding ryanodine receptor) account for 70% of cases.

Clinical Features:

Earliest sign: Unexplained increase in end-tidal CO₂
Masseter muscle rigidity (especially after succinylcholine)
Generalized rigidity
Hyperthermia (may be a late sign, temperature rises 1-2°C every 5 minutes)
Tachycardia, arrhythmias
Metabolic acidosis, hyperkalemia
Mottled skin, cyanosis

**Diagnostic Scoring (Clinical Grading Scale):**⁸ Points assigned for rigidity, muscle breakdown, respiratory acidosis, temperature increase, cardiac involvement, family history. Score >50 = very likely MH.

Pearl #4: MH is primarily a perioperative diagnosis, but consider it in ICU patients receiving total intravenous anesthesia (TIVA) for procedures if volatile agents are inadvertently used or if propofol infusion syndrome develops with similar presentation.

Management:

Immediate discontinuation of triggering agents
Hyperventilation with 100% O₂ (10-15 L/min)
Dantrolene sodium: 2.5 mg/kg rapid IV bolus
- Repeat q5min until symptoms controlled (up to 10 mg/kg initially)
- Maintenance: 1 mg/kg q6h × 24-48 hours
Active cooling: Cold saline IV, surface cooling, gastric/bladder lavage
Treatment of complications:
- Hyperkalemia: insulin-glucose, calcium, hyperventilation
- Acidosis: sodium bicarbonate
- Arrhythmias: avoid calcium channel blockers with dantrolene (risk of hyperkalemia and cardiovascular collapse)
Urine alkalinization: Prevent myoglobin precipitation

Hack #3: Keep dantrolene immediately available in all locations where triggering agents are used. Reconstituting the old formulation requires 60 mL sterile water per 20 mg vial—a full treatment dose may require mixing 36 vials, taking 20+ minutes. Newer formulations (Ryanodex®) dissolve more rapidly.

4. Central Nervous System Infections

Bacterial Meningitis

Despite advances in vaccination, bacterial meningitis remains a medical emergency with mortality rates of 15-25%.⁹

Clinical Triad (present in <50% of patients):

Fever
Neck stiffness
Altered mental status

Pearl #5: *In one landmark study, 95% of adults with bacterial meningitis had at least 2 of 4 features: headache, fever, neck stiffness, or altered mental status. However, absence of all four features has a 99% negative predictive value.*¹⁰

Physical Examination:

Nuchal rigidity: Passive neck flexion resistance
Kernig's sign: Pain/resistance with knee extension when hip flexed 90°
Brudzinski's sign: Hip/knee flexion with passive neck flexion
Sensitivity of meningeal signs: 30-70% (lower in elderly, immunocompromised)

Diagnostic Approach:

Blood cultures: Before antibiotics (positive in 50-90%)
Empiric antibiotics: Do NOT delay for imaging/LP if presentation is classic
**Head CT indications before LP:**¹¹
- Immunocompromised state
- History of CNS disease
- New-onset seizure (within 1 week)
- Papilledema
- Abnormal level of consciousness
- Focal neurological deficit
Lumbar puncture:
- Opening pressure
- Cell count and differential
- Glucose, protein
- Gram stain and culture
- Consider: PCR for S. pneumoniae, N. meningitidis, HSV, enterovirus

CSF Interpretation:

Parameter	Bacterial	Viral	Tuberculous
Appearance	Turbid	Clear	Clear/fibrin web
Pressure	Elevated	Normal/↑	Elevated
WBC count	>1000	<1000	10-500
Predominant cell	PMN >80%	Lymphocyte	Lymphocyte
Protein (mg/dL)	>250	<200	>100
Glucose	<40 or CSF:serum <0.4	Normal	<45

**Empiric Antibiotic Therapy (before organism identification):**¹²

Immunocompetent adults <50 years:
- Vancomycin 15-20 mg/kg IV q8-12h PLUS
- Ceftriaxone 2 g IV q12h
Adults >50 years or alcoholism/immunocompromised:
- Add ampicillin 2 g IV q4h (for Listeria)
Post-neurosurgery/CSF shunt:
- Vancomycin PLUS cefepime or meropenem (for Pseudomonas, Acinetobacter)
Adjunctive dexamethasone:
- 10 mg IV q6h × 4 days (start just before or with first antibiotic dose)
- Reduces mortality in pneumococcal meningitis
- Administer only if bacterial meningitis is likely; discontinue if another etiology confirmed

Oyster #2: The dictum "never delay antibiotics for LP or imaging" is correct, but be aware that antibiotics can sterilize CSF cultures within 2-4 hours. If LP is delayed, consider PCR testing and blood cultures, which remain valuable. In viral meningitis, patients may still have significant rigidity from meningeal irritation—don't anchor on bacterial meningitis exclusively.

Viral Encephalitis

Encephalitis presents with fever, altered consciousness, and often seizures. Rigidity may occur due to generalized increased tone or secondary to seizures.

Most Common Causes:

Herpes simplex virus (HSV-1): Most common, 10-20% of viral encephalitis
Varicella-zoster virus (VZV)
Enteroviruses
Arboviruses (West Nile, Japanese encephalitis)
Autoimmune (anti-NMDA receptor encephalitis)

Pearl #6: *HSV encephalitis should be treated empirically with acyclovir 10 mg/kg IV q8h in any patient with encephalitis until HSV PCR returns negative. Don't wait for MRI confirmation—temporal lobe involvement on imaging is seen in only 80% during the first 48 hours, and treatment delay increases mortality.*¹³

Diagnostic Evaluation:

CSF: Lymphocytic pleocytosis, elevated protein, normal glucose
CSF PCR: HSV, VZV, enterovirus
MRI: Temporal lobe involvement (HSV), bilateral thalami (arbovirus)
EEG: Periodic lateralized epileptiform discharges (PLEDs) in HSV

5. Tetanus

Tetanus, caused by Clostridium tetani exotoxin (tetanospasmin), remains a concern in unvaccinated or inadequately vaccinated patients, particularly in developing nations and among elderly populations in developed countries.¹⁴

Clinical Features:

Trismus (lockjaw): Masseter muscle spasm—earliest sign in 75%
Risus sardonicus: Facial muscle spasm causing characteristic grin
Opisthotonos: Severe back arching from extensor spasm
Generalized rigidity: Board-like abdomen
Painful muscle spasms: Triggered by stimuli (noise, light, touch)
Autonomic instability: Labile BP, tachycardia, arrhythmias, diaphoresis
Fever: Usually mild, but severe spasms generate heat
Normal mental status: Consciousness typically preserved

**Ablett Classification:**¹⁵

Grade I (Mild): Trismus, no spasms
Grade II (Moderate): Trismus, rigidity, mild spasms, dysphagia
Grade III (Severe): Reflex spasms, tachypnea, tachycardia
Grade IV (Very severe): Grade III plus severe autonomic dysfunction

Pearl #7: *The spatula test is highly specific for tetanus: Touch the posterior pharyngeal wall with a tongue depressor. In tetanus, involuntary biting of the spatula occurs (positive test). In non-tetanus, a gag reflex occurs. Sensitivity 94%, specificity 100%.*¹⁶

Management:

Airway management: Early intubation before laryngospasm occurs
Wound debridement: Remove necrotic tissue/foreign bodies
Human tetanus immunoglobulin (HTIG): 500 units IM (3000-6000 units for clinical tetanus)
- Neutralizes unbound toxin
- Administer at site distant from vaccine
Tetanus toxoid vaccine: 0.5 mL IM (initiate immunization series)
Antibiotic therapy:
- Metronidazole 500 mg IV q6h × 7-10 days (preferred)
- Alternative: Penicillin G 2-4 million units IV q4-6h
Control of spasms:
- Benzodiazepines: Diazepam 10-40 mg q3-6h (may require very high doses)
- Magnesium sulfate: 5 g IV loading, then 2-3 g/h infusion
- Neuromuscular blockade + mechanical ventilation (severe cases)
- Intrathecal baclofen (refractory cases)
Autonomic management:
- Magnesium sulfate (first-line)
- Avoid β-blockers (may precipitate cardiovascular collapse)
- Morphine infusion for sympathetic overactivity
- Clonidine, dexmedetomidine (alternatives)
Supportive care:
- Minimize stimulation (dark, quiet room)
- Tracheostomy for prolonged ventilation
- DVT prophylaxis
- Nutritional support

Hack #4: *Magnesium sulfate is the unsung hero in tetanus management. It reduces spasm frequency, controls autonomic dysfunction, and has a better safety profile than traditional therapies. Target serum magnesium of 2-4 mmol/L (4-8 mg/dL).*¹⁷

Oyster #3: Tetanus is a clinical diagnosis—no laboratory test confirms it. Wound cultures are positive in only 30% of cases. Recovery from tetanus does NOT confer immunity—patients must complete vaccination series. The differential includes strychnine poisoning (rare), which presents similarly but with intermittent relaxation between spasms and often a history of rodenticide exposure.

6. Status Epilepticus with Post-ictal Rigidity

Convulsive status epilepticus (CSE) may present with persistent rigidity in the post-ictal phase or during non-convulsive status epilepticus (NCSE).

Definition: Seizure lasting >5 minutes or recurrent seizures without return to baseline between episodes.¹⁸

Clinical Features:

Tonic rigidity during tonic phase of seizure
Post-ictal rigidity and altered consciousness
Hyperthermia from sustained muscular activity
Lactic acidosis, elevated CK

Pearl #8: *Always consider NCSE in ICU patients with unexplained altered mental status and fever. Up to 48% of comatose patients without overt seizures may have NCSE on continuous EEG monitoring.*¹⁹

Management:

Standard status epilepticus protocol
Temperature management
EEG monitoring to confirm seizure cessation

Other Important Differentials

7. Stiff-Person Syndrome (SPS)

Rare autoimmune disorder characterized by progressive muscle rigidity and spasms. Associated with anti-GAD antibodies. Fever may occur with acute exacerbations or secondary infections.²⁰

Features:

Chronic progressive course (vs. acute in other syndromes)
Axial and limb rigidity (lumber hyperlordosis)
Stimulus-triggered spasms
Improvement with benzodiazepines and GABA agonists

8. Anticholinergic Toxicity

Anticholinergic syndrome can present with fever and increased muscle tone, though typically not true rigidity.

Classic presentation: "Hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter"

Mydriasis, dry mucous membranes
Urinary retention
Absent bowel sounds
Agitation, delirium

Management: Physostigmine in severe cases (contraindicated if TCA ingestion or QRS widening)

9. Heat Stroke

Environmental or exertional heat stroke presents with core temperature >40°C and CNS dysfunction.

Types:

Classic (passive): Environmental exposure, elderly
Exertional: Young, vigorous activity

Features:

Anhidrosis (in classic heat stroke)
Altered mental status
Multiorgan dysfunction
Rigidity may be absent but increased tone common

Management:

Immediate cooling to <38.5°C within 30-60 minutes
Evaporative cooling, ice packs, cold saline infusion
Avoid antipyretics (ineffective)

10. Thyroid Storm

Extreme thyrotoxicosis presenting with fever, tachycardia, and tremor (not true rigidity). Burch-Wartofsky score >45 suggests thyroid storm.²¹

Management:

β-blockade (propranolol 1-2 mg IV)
Thionamides (PTU or methimazole)
Inorganic iodine (after thionamides)
Corticosteroids
Cooling measures

Diagnostic Approach

Initial Assessment

Hack #5: Use the "FEVER + RIGIDITY" mnemonic for rapid systematic assessment:

F - Focus on timing: Acute (<24h) vs. subacute vs. chronic E - Exposure history: Drugs, anesthesia, environment, toxinsV - Vital signs: Temperature pattern, autonomic instability E - Examination: Type of rigidity, reflexes, clonus, mental status R - Review medications: Last 4 weeks, recent changes, interactions

R - Reflexes and tone: Hyper vs. hypo, distribution I - Infection workup: Blood cultures, urinalysis, imaging G - Get basic labs: CK, metabolic panel, CBC, blood gas I - Imaging: CT head if indicated before LP D - Diagnostic LP: If meningitis/encephalitis considered I - Identify reversible causes: Immediately treatable conditions T - Treatment: Don't delay empiric therapy Y - Yield: Continuous monitoring and reassessment

Critical Initial Investigations

Essential labs:

Complete blood count with differential
Comprehensive metabolic panel
Creatine kinase, myoglobin
Arterial or venous blood gas
Lactate
Blood cultures × 2
Urinalysis and culture
Toxicology screen
Thyroid function tests (if indicated)

Essential imaging:

CT head (before LP if indicated)
Chest X-ray

Additional testing as indicated:

Lumbar puncture with opening pressure
EEG
MRI brain
Specific drug levels
Autoimmune encephalitis panel

Management Principles

General Supportive Measures

Airway protection: Early intubation for altered mental status, inability to protect airway, or severe rigidity affecting ventilation
Temperature management:
- External cooling: Cooling blankets, ice packs to groin/axillae/neck
- Internal cooling: Cold IV saline (4°C), gastric/bladder lavage
- Avoid aggressive cooling in true fever (may cause shivering, increasing heat production)
- Target: <38.5°C in hyperthermia syndromes
Hemodynamic support:
- Aggressive IV fluid resuscitation
- Vasopressors for refractory hypotension
- Continuous cardiac monitoring
Rhabdomyolysis management:
- Aggressive fluid resuscitation (200-300 mL/h)
- Target urine output >200 mL/h
- Urine alkalinization: Sodium bicarbonate (controversial)
- Monitor: Potassium, calcium, phosphate
- Renal replacement therapy if indicated
Seizure prophylaxis: Benzodiazepines for drug-induced hyperthermic syndromes

Pearl #9: In hyperthermic syndromes with rigidity, neuromuscular blockade facilitates cooling but masks the clinical endpoint. If paralysis is necessary, maintain continuous core temperature monitoring and consider continuous EEG to detect ongoing seizure activity.

Specific Antidotes and Treatments

Condition	Specific Treatment	Mechanism	Dose
NMS	Dantrolene	↓ Calcium release	1-2.5 mg/kg IV q6h
	Bromocriptine	Dopamine agonist	2.5-10 mg PO TID
Serotonin Syndrome	Cyproheptadine	5-HT₂A antagonist	12 mg initial, then 2 mg q2h
Malignant Hyperthermia	Dantrolene	↓ Calcium release	2.5 mg/kg IV bolus, repeat
Bacterial Meningitis	Vancomycin + Ceftriaxone	Bactericidal	See dosing above
	Dexamethasone	↓ Inflammation	10 mg IV q6h × 4 days
HSV Encephalitis	Acyclovir	Antiviral	10 mg/kg IV q8h
Tetanus	HTIG	Toxin neutralization	500-6000 units IM
	Magnesium sulfate	Multiple	5 g load, 2-3 g/h

Clinical Pearls Summary

Pearl #10: The "Dantrolene vs. Cyproheptadine" decision is crucial and time-sensitive. Key differentiators:

Feature	NMS	Serotonin Syndrome
Onset	Days to weeks	Hours
Rigidity	Uniform, "lead pipe"	Lower extremity predominant
Reflexes	Normal or ↓	Hyperreflexia
Clonus	Absent	Present (inducible/spontaneous)
Pupils	Normal	Mydriasis
Tremor	Rare	Common
Treatment	Dantrolene + Bromocriptine	Cyproheptadine

Pearl #11: CK elevation helps differentiate drug-induced hyperthermic syndromes from CNS infections:

NMS/MH: CK typically >1,000 U/L, often >10,000 U/L
Serotonin syndrome: CK usually <1,000 U/L (unless severe)
Meningitis/encephalitis: CK normal or mildly elevated

Pearl #12: Autonomic instability patterns can guide diagnosis:

Labile/paroxysmal (fluctuating BP, HR): Tetanus, autonomic dysfunction
Sustained hypertension + tachycardia: Serotonin syndrome, NMS
Hypotension: Septic shock, severe NMS, advanced heat stroke

Prognostic Factors

Poor Prognostic Indicators

**NMS:**²²

Temperature >40°C
CK >10,000 U/L
Acute kidney injury requiring dialysis
Development of DIC
Delayed recognition (>24 hours)

**Bacterial Meningitis:**⁹

Altered consciousness at presentation
Seizures
Hypotension
Delayed antibiotic administration (>3 hours from arrival)
Age >60 years
Immunocompromised state

**Tetanus:**¹⁴

Ablett grade III-IV
Incubation period <7 days
Period of onset <48 hours (time from first symptom to first spasm)
Autonomic dysfunction
Age >60 years

**Malignant Hyperthermia:**⁷

Peak temperature >44°C
Delay in dantrolene administration
Cardiac arrest
Multiple triggering agent exposures

Prevention Strategies

Pharmacovigilance:
- Review drug interactions before prescribing serotonergic agents
- Minimum 2-week washout between MAO inhibitors and SSRIs (5 weeks for fluoxetine)
- Monitor high-risk patients (elderly, polypharmacy) when initiating antipsychotics
- Avoid triggering agents in patients with MH family history
Vaccination:
- Universal tetanus vaccination: Primary series plus boosters every 10 years
- Post-exposure prophylaxis for inadequately immunized patients
- Pneumococcal and meningococcal vaccination for high-risk groups
Infection control:
- Droplet precautions for suspected meningococcal meningitis
- Standard precautions for other bacterial meningitis
Early recognition protocols:
- ICU screening tools for drug-induced syndromes in patients receiving high-risk medications
- Immediate notification systems for perioperative MH signs

Conclusion

Fever and rigidity in the critically ill patient represents a true medical emergency requiring immediate systematic evaluation and often empiric treatment. The differential diagnosis spans infectious, toxicologic, metabolic, and autoimmune etiologies, each with specific management strategies and prognostic implications.

The key to optimal outcomes lies in:

Rapid recognition of life-threatening syndromes (NMS, serotonin syndrome, MH, bacterial meningitis, tetanus)
Immediate empiric therapy without waiting for confirmatory testing
Aggressive supportive care including cooling, fluid resuscitation, and organ support
Continuous reassessment and adjustment of working diagnosis based on clinical evolution
Multidisciplinary collaboration involving critical care, neurology, infectious diseases, and pharmacy

As critical care practitioners, our challenge is to maintain a high index of suspicion, employ a systematic diagnostic approach, and initiate appropriate interventions rapidly—recognizing that minutes may determine the difference between full recovery and devastating neurological injury or death.

Final Hack: In the undifferentiated patient with fever and rigidity where the diagnosis is unclear, the safest approach is often to treat the most immediately life-threatening possibilities simultaneously: Start empiric antibiotics and dexamethasone for bacterial meningitis, discontinue all potentially causative drugs (antipsychotics, serotonergics), initiate cooling measures, and consider empiric benzodiazepines while awaiting diagnostic clarity. Better to overtreat temporarily than to delay specific therapy for a catastrophic condition.

References

Laupland KB. Fever in the critically ill medical patient. Crit Care Med. 2009;37(7 Suppl):S273-S278.
Walter EJ, Carraretto M. The neurological and cognitive consequences of hyperthermia. Crit Care. 2016;20(1):199.
Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876.
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395-406.
Boyer EW,

Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.

Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology. 2008;108(4):603-611.
van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-S62.
Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA. 1999;282(2):175-181.
Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 2001;345(24):1727-1733.
Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284.
Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64(4):347-373.
Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-1443.
Ablett JJ. Analysis and main experiences in 82 patients treated in the Leeds Tetanus Unit. In: Ellis M, ed. Symposium on Tetanus in Great Britain. Boston Spa, UK: National Lending Library for Science and Technology; 1967:1-10.
Apte NM, Karnad DR. The spatula test: a simple bedside test to diagnose tetanus. Am J Trop Med Hyg. 1995;53(4):386-387.
Thwaites CL, Yen LM, Glover C, et al. Predicting the clinical outcome of tetanus: the tetanus severity score. Trop Med Int Health. 2006;11(3):279-287.
Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology. 2000;54(2):340-345.
Hadavi S, Noyce AJ, Leslie RD, Giovannoni G. Stiff person syndrome. Pract Neurol. 2011;11(5):272-282.
Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22(2):263-277.
Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018;20(1):17r02185.
Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P; West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg. 2012;99(11):1501-1513.
Simon LV, Hashmi MF, Farrell MW. Hypermagnesemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.
Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100-109.
Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021;76(5):655-664.
Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;2015(9):CD004405.
Tyler KL. Acute viral encephalitis. N Engl J Med. 2018;379(6):557-566.
Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry. 2000;69(3):292-301.
Gibson K, Bonaventure Uwineza J, Kiviri W, Parlow J. Tetanus in developing countries: a case series and review. Can J Anaesth. 2009;56(4):307-315.
Alerhand S, Lay C, Cassara M. Serotonin syndrome in the ED: an evidenced-based approach to recognition and management. Am J Emerg Med. 2021;44:370-375.
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 2000;18(2):317-325.
Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology. 2018;128(1):159-167.
Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105(4):417-420.
Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4(4):CD002244.
McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults. Lancet. 2016;388(10063):3036-3047.
Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth. 2001;87(3):477-487.
Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18(2):217.

Additional Clinical Scenarios and Teaching Points

Case-Based Learning Scenarios

Scenario 1: The Missed Diagnosis

Presentation: A 68-year-old woman with depression presents with 3-day history of confusion and falls. Nursing home started citalopram 10 days ago. Temperature 38.9°C, BP 165/95, HR 118. She is agitated with increased tone in lower extremities. CK is 450 U/L.

Question: Why might this be misdiagnosed as NMS?

Recent psychotropic medication
Elevated CK
Altered mental status and rigidity

Answer: This is serotonin syndrome, not NMS. Key differentiators:

Citalopram is an SSRI (serotonergic), not antipsychotic
Lower extremity predominance of rigidity
Relatively low CK (<1,000)
Check for hyperreflexia and clonus (often missed on initial exam)

Teaching Point: Always check ankle clonus in any patient on serotonergic agents with altered mental status and fever. The finding of sustained clonus (>5 beats) is nearly diagnostic of serotonin syndrome and changes management completely.

Scenario 2: The Drug Interaction

Presentation: Post-operative day 3 following bowel surgery. Patient receiving tramadol for pain and ondansetron for nausea. Develops agitation, diaphoresis, temperature 39.2°C, tremor, and hyperreflexia.

Question: What is the mechanism? Answer: Both tramadol (weak serotonin reuptake inhibitor + releases serotonin) and ondansetron (5-HT₃ antagonist with some 5-HT₂ agonism) are serotonergic agents. The combination can precipitate serotonin syndrome.

Teaching Point: Ondansetron and other antiemetics (metoclopramide) are commonly overlooked contributors to serotonin syndrome. When reviewing medications for serotonergic agents, think beyond antidepressants: analgesics (tramadol, meperidine, fentanyl), antiemetics, antibiotics (linezolid), and even over-the-counter products (dextromethorphan, St. John's wort).

Scenario 3: The Delayed Presentation

Presentation: A 45-year-old farmer presents with inability to open mouth × 2 days, now with board-like abdominal rigidity and back arching. He stepped on a rusty nail 10 days ago but didn't seek treatment. Temperature 37.8°C initially, but rises to 39.5°C with frequent painful spasms.

Question: Why is the fever pattern important? Answer: In tetanus, fever is often initially absent or mild and develops secondary to the heat generated by sustained muscular contractions and spasms. This contrasts with infectious causes where fever typically precedes or accompanies rigidity.

Teaching Point: The incubation period (injury to first symptom) and period of onset (first symptom to first spasm) in tetanus have prognostic value. Short periods (<7 days incubation, <48 hours onset) indicate severe disease with higher mortality. Document these intervals when taking the history.

Advanced Management Considerations

Refractory Cases

When first-line treatments fail:

Refractory NMS:
- Consider electroconvulsive therapy (ECT)
- Case reports show improvement within 3-10 sessions
- Mechanism: Uncertain, may enhance dopaminergic transmission
- Consider early in malignant cases or when dantrolene/bromocriptine ineffective after 48-72 hours²⁵
Refractory Serotonin Syndrome:
- Neuromuscular blockade with non-depolarizing agents
- Chlorpromazine 25-50 mg IM (alternative 5-HT antagonist)
- Caution: Chlorpromazine can lower seizure threshold and cause hypotension
- Propofol infusion for sedation (avoid in propofol infusion syndrome risk patients)²⁶
Refractory Tetanus Spasms:
- Intrathecal baclofen: 50-2000 mcg/day via pump
- Requires neurosurgical consultation
- Reduces spasm frequency and benzodiazepine requirements
- Particularly useful when systemic therapy causes excessive sedation
- Vecuronium or rocuronium continuous infusion for complete neuromuscular blockade
- Requires prolonged mechanical ventilation (weeks)

Oyster #4: In refractory hyperthermic syndromes, consider early consultation with ECMO centers. Veno-venous ECMO provides both oxygenation and efficient core cooling. Case reports demonstrate successful rescue in MH and severe heat stroke when conventional cooling methods fail.

Special Populations

Elderly Patients:

Higher mortality from all fever-rigidity syndromes
Atypical presentations common (absence of classic features)
Meningitis may present without neck stiffness (sensitivity <50% in >65 years)
Lower threshold for empiric antibiotic therapy
Increased risk of adverse effects from treatments (dantrolene hepatotoxicity, benzodiazepine over-sedation)

Pregnant Patients:

Bacterial meningitis: No change in antibiotic approach, dexamethasone considered safe
Serotonin syndrome: Cyproheptadine Category B, generally safe
NMS: Dantrolene Category C, but benefit likely outweighs risk
Tetanus: HTIG and antibiotics safe; magnesium requires monitoring (can potentiate neuromuscular blockade, delay labor)
Consider fetal monitoring in viable pregnancies

Immunocompromised Patients:

Broader differential: Listeria, fungi, mycobacteria, opportunistic viruses (CMV, HHV-6)
Empiric ampicillin mandatory for Listeria coverage
Consider voriconazole or amphotericin for fungal meningitis
Lower threshold for brain biopsy if CSF non-diagnostic
Anti-NMDA receptor encephalitis association with ovarian teratomas

Medicolegal Considerations

Documentation Imperatives:

Timing documentation:
- Exact time of symptom recognition
- Time of medication discontinuation
- Time of specific antidote administration
- Delays in diagnosis are frequently cited in litigation
Decision-making rationale:
- Why LP was delayed or CT obtained first
- Rationale for empiric antibiotic selection
- Reason for not administering specific therapy (e.g., "dantrolene not given because Hunter criteria met, suggesting serotonin syndrome rather than NMS")
Informed consent discussions:
- Risks of LP (rare but serious: herniation, bleeding)
- Risks of empiric therapy before diagnosis confirmed
- Prognosis discussion with family
Consultation documentation:
- Neurology for encephalitis/seizures
- Infectious diseases for complex meningitis
- Toxicology for drug-induced syndromes
- Note recommendations and implementation

Pearl #13: In medicolegal reviews, the most common criticism is "failure to consider" a diagnosis, not "failure to correctly diagnose." Document your differential diagnosis explicitly, including what you considered and ruled out, even if the diagnosis seems obvious in retrospect.

Quality Improvement and Systems-Based Practice

ICU Protocol Development

Suggested protocol components:

Screening tool for drug-induced hyperthermic syndromes:
- Automated pharmacy alerts for high-risk drug combinations
- Daily ICU checklist item: "Patient on serotonergic/dopaminergic agents? Any signs of toxicity?"
Fever and rigidity rapid response pathway:
- Triggers immediate senior physician evaluation
- Standardized order set including:
  - Stat laboratories (CK, metabolic panel, lactate, blood cultures)
  - Discontinuation of potentially causative agents
  - Cooling measures
  - Consider empiric antibiotics pending LP
Time-sensitive treatment metrics:
- Door-to-antibiotic time for suspected bacterial meningitis (goal <60 minutes)
- Drug discontinuation to dantrolene time for suspected NMS (goal <30 minutes)
- Recognition to cooling initiation for hyperthermia (goal <15 minutes)
MH cart/crisis kit:
- Dantrolene (36 vials of 20 mg or equivalent Ryanodex®)
- Sodium bicarbonate
- Insulin and dextrose for hyperkalemia
- MH crisis checklist laminated card
- Annual drills and competency assessment

Hack #6: Create a "fever + rigidity" badge-card for all ICU providers with a decision tree on one side and specific dosing for dantrolene, cyproheptadine, magnesium, and empiric antibiotics on the reverse. Cognitive aids reduce diagnostic errors and treatment delays in rare, high-stakes scenarios.

Emerging Evidence and Future Directions

Novel Diagnostics

Point-of-care CSF testing:
- Multiplex PCR panels can identify 14+ pathogens in <1 hour
- Includes bacteria (S. pneumoniae, N. meningitidis, H. influenzae, L. monocytogenes), viruses (HSV-1/2, VZV, enteroviruses), fungi (Cryptococcus), and yeast
- Sensitivity 90-95% for bacterial pathogens
- May not detect organisms if antibiotics already administered
Biomarkers:
- Serum procalcitonin: Elevated in bacterial meningitis (>0.5 ng/mL), normal in viral
- CSF lactate: >4 mmol/L suggests bacterial etiology (sensitivity 93%, specificity 94%)
- Promising but not yet standard of care
Continuous EEG monitoring:
- Increasingly available in ICU settings
- Critical for detecting NCSE in patients with unexplained altered consciousness
- May identify subclinical seizures contributing to fever and rigidity

Therapeutic Advances

Targeted temperature management devices:
- Intravascular cooling catheters provide precise temperature control
- Surface cooling pads with feedback mechanisms
- Automated systems reduce nursing workload and temperature variability
Neuroprotective strategies:
- Hypothermia protocols after successful cooling from hyperthermia
- Anti-inflammatory adjuncts for CNS infections (beyond dexamethasone)
- Ongoing trials of various neuroprotective agents
Genetic screening:
- Pre-operative MH susceptibility testing using genetic panels (RYR1, CACNA1S mutations)
- Pharmacogenomic testing for drug metabolism variants predisposing to NMS/serotonin syndrome
- Currently limited by cost and availability

Global Health Perspective

Resource-Limited Settings

Fever and rigidity syndromes have different epidemiology and management challenges in low- and middle-income countries:

Tetanus:

Remains a significant problem due to incomplete vaccination coverage
Neonatal tetanus from non-sterile umbilical cord care
Limited access to HTIG, ICU facilities, and mechanical ventilation
WHO-recommended simplified management protocols³¹

Bacterial Meningitis:

"Meningitis belt" in sub-Saharan Africa with epidemic meningococcal disease
Tuberculousmeningitis more common
Limited access to CT, prolonged delays to LP
Empiric treatment often all that's available

Adaptations for resource-limited settings:

Clinical diagnosis without confirmatory testing
Affordable alternatives: Penicillin instead of ceftriaxone for pneumococcal meningitis (where resistance rates low)
Magnesium sulfate instead of benzodiazepines for tetanus (lower cost, widely available)
Community-based prevention: Mass vaccination campaigns, birth attendant training

Pearl #14: In travelers returning from endemic areas with fever and rigidity, expand the differential to include cerebral malaria, Japanese encephalitis, rabies, and typhoid fever with neurological complications. Always obtain a detailed travel history including specific regions, activities, and vaccination status.

Educational Strategies for Teaching

For medical educators teaching fever and rigidity syndromes:

Simulation-Based Learning:

High-fidelity scenarios for MH crisis, NMS recognition
Emphasis on crisis resource management and team communication
Debriefing focused on cognitive errors (anchoring bias, premature closure)

Pattern Recognition Training:

Side-by-side comparison of video examples showing different rigidity types
Practice examining for hyperreflexia, clonus, and autonomic signs
Bedside teaching emphasizing subtle examination findings

Cognitive Load Reduction:

Mnemonics and decision aids (as provided in this review)
Spaced repetition of rare but critical diagnoses
Integration into existing critical care curricula rather than standalone teaching

Interdisciplinary Education:

Joint sessions with pharmacy (drug interactions, serotonin syndrome risk)
Collaboration with neurology (examination techniques, EEG interpretation)
Infection control partnerships (meningitis prophylaxis protocols)

Summary: The "Must-Know" Essentials

For the time-pressured clinician, here are the absolutely essential points:

The "Can't-Miss" Diagnoses

Bacterial meningitis (empiric antibiotics immediately)
NMS (discontinue antipsychotic, give dantrolene)
Serotonin syndrome (discontinue serotonergics, give cyproheptadine)
Malignant hyperthermia (discontinue triggers, give dantrolene)
Tetanus (HTIG, antibiotics, magnesium, airway)

The "Must-Do" Actions

Stabilize first: Airway, cooling, fluids
Stop the cause: Discontinue all potentially offending drugs
Start empiric treatment: Don't wait for confirmation
Get key tests: CK, CSF if safe, blood cultures
Consult early: Neurology, infectious diseases, toxicology as appropriate

The "Must-Remember" Differentiators

Clonus = Serotonin syndrome (not NMS)
CK >10,000 = NMS or MH (not serotonin syndrome)
Normal consciousness = Tetanus (not encephalitis)
Temporal lobe focus = HSV encephalitis (start acyclovir)
Perioperative onset = MH until proven otherwise

Conclusion

The approach to fever and rigidity in critical care demands a synthesis of rapid clinical assessment, pattern recognition, judicious use of diagnostics, and aggressive empiric therapy. While this review has covered extensive ground, the fundamental principle remains simple: Think systematically, act decisively, and don't let the perfect be the enemy of the good when treating life-threatening conditions.

The art of critical care medicine lies not in waiting for diagnostic certainty, but in acting on clinical probability to prevent irreversible harm. In fever-rigidity syndromes, this often means treating for multiple potential etiologies simultaneously while the diagnostic workup proceeds—a perfectly reasonable approach when the stakes are measured in neurological function and survival.

As you apply these principles at the bedside, remember that protocols and mnemonics are cognitive aids, not substitutes for clinical judgment. Every patient requires individualized assessment, and every clinical scenario offers an opportunity to refine your diagnostic acumen.

Stay vigilant, think broadly, and treat aggressively.

This review is intended for educational purposes and should not replace clinical judgment or institutional protocols. Treatment recommendations should be adapted to local antimicrobial resistance patterns, drug availability, and patient-specific factors.

Disclosure: The author reports no conflicts of interest.

Acknowledgments: The author thanks the critical care and neurology colleagues who contributed clinical insights to this review.

Friday, October 17, 2025